171 related articles for article (PubMed ID: 37674872)
1. MCM-2 Levels as a Potential Biomarker for Predicting High-Risk Breast Cancer Patients According to TAILORx Classification.
Ünal Ç; Özmen T; İlgün AS; Ordu Ç; Özkurt E; Ak N; Alço G; Erdoğan İyigün Z; Kurt S; Duymaz T; Öztürk MA; Elbüken Çelebi F; Yararbaş K; Soybir G; Aktepe F; Özmen V
Breast Cancer (Dove Med Press); 2023; 15():659-669. PubMed ID: 37674872
[TBL] [Abstract][Full Text] [Related]
2. Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey.
Ünal Ç; Özmen T; Ordu Ç; Pilanci KN; İlgün AS; Gökmen E; Almuradova E; Özdoğan M; Güler N; Uras C; Kara H; Demircan O; Işık S; Alço G; Saip P; Aydın E; Duymaz T; Çelebi F; Yararbaş K; Soybir G; Ozmen V
Front Oncol; 2023; 13():1151733. PubMed ID: 37448522
[TBL] [Abstract][Full Text] [Related]
3. Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review.
Glasgow A; Sechrist H; Bomeisl P; Gilmore H; Harbhajanka A
Breast Cancer; 2021 Mar; 28(2):321-328. PubMed ID: 32951186
[TBL] [Abstract][Full Text] [Related]
4. Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.
Orucevic A; Bell JL; McNabb AP; Heidel RE
Breast Cancer Res Treat; 2017 May; 163(1):51-61. PubMed ID: 28243897
[TBL] [Abstract][Full Text] [Related]
5. Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and ≥31.
Berger NF; Zimmerman BS; Tharakan S; Suchman K; Cascetta KP; Blanter J; Moshier E; Ru M; Jaffer S; Tiersten A
Oncology; 2021; 99(11):699-702. PubMed ID: 34425579
[TBL] [Abstract][Full Text] [Related]
6. Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data.
Orucevic A; Bell JL; King M; McNabb AP; Heidel RE
Breast; 2019 Aug; 46():116-125. PubMed ID: 31146185
[TBL] [Abstract][Full Text] [Related]
7. The added value of ultrasound imaging biomarkers to clinicopathological factors for the prediction of high-risk Oncotype DX recurrence scores in patients with breast cancer.
Luo Y; Gao Y; Niu Z; Zhang J; Liu Z; Zhang Y; Shen S; Jiang Y; Xiao M; Zhu Q
Quant Imaging Med Surg; 2024 May; 14(5):3519-3533. PubMed ID: 38720854
[TBL] [Abstract][Full Text] [Related]
8. The Oncotype DX Recurrence Score's Impact on the Management of Oestrogen-Positive/Human Epidermal Growth Factor Receptor 2-Negative, Low-Burden Axillary Status Breast Cancer (REHAB Study): Results of a Single Centre.
Saad Abdalla Al-Zawi A; Yin SL; Mahmood B; Jalil A; Aladili Z
Cureus; 2022 Jul; 14(7):e27341. PubMed ID: 36042999
[TBL] [Abstract][Full Text] [Related]
9. Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis.
Ingoldsby H; Webber M; Wall D; Scarrott C; Newell J; Callagy G
Breast; 2013 Oct; 22(5):879-86. PubMed ID: 23643806
[TBL] [Abstract][Full Text] [Related]
10. Correlation Between Oncotype DX, PREDICT and the Nottingham Prognostic Index: Implications for the Management of Early Breast Cancer.
Hillyar C; Rizki H; Abbassi O; Miles-Dua S; Clayton G; Gandamihardja T; Smith S
Cureus; 2020 Apr; 12(4):e7552. PubMed ID: 32382456
[TBL] [Abstract][Full Text] [Related]
11. Prediction of Oncotype DX Recurrence Score Using Clinicopathological Variables in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
Kim MC; Kwon SY; Choi JE; Kang SH; Bae YK
J Breast Cancer; 2023 Apr; 26(2):105-116. PubMed ID: 37095618
[TBL] [Abstract][Full Text] [Related]
12. Association Between Ki-67 Proliferative Index and Oncotype-Dx Recurrence Score in Hormone Receptor-Positive, HER2-Negative Early Breast Cancers. A Systematic Review of the Literature.
Mooghal M; Khan MAA; Samar MR; Shaikh H; Valimohammad AT; Idrees R; Abdul Rashid Y; Sattar AK
Breast Cancer (Auckl); 2024; 18():11782234241255211. PubMed ID: 38779417
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study.
Oliveira LJC; Megid TBC; Rosa DD; Magliano CADS; Assad DX; Argolo DF; Sanches SM; Testa L; Bines J; Kaliks R; Caleffi M; de Melo Gagliato D; Sahade M; Barroso-Sousa R; Corrêa TS; Shimada AK; Batista DN; Musse Gomes D; Cesca MG; Gaudêncio D; Moura LMA; de Araújo JAP; Katz A; Mano MS
Ther Adv Med Oncol; 2022; 14():17588359221141760. PubMed ID: 36601632
[TBL] [Abstract][Full Text] [Related]
14. Identifying Clinicopathological Factors Associated with Oncotype DX
Gagnet S; Diorio C; Provencher L; Mbuya-Bienge C; Lapointe J; Morin C; Lemieux J; Nabi H
J Pers Med; 2021 Aug; 11(9):. PubMed ID: 34575635
[TBL] [Abstract][Full Text] [Related]
15. Is Age Trumping Genetic Profiling in Clinical Practice? Relationship of Chemotherapy Recommendation and Oncotype DX Recurrence Score in Patients Aged < 50 Years versus ≥ 50 Years, and Trends Over Time.
Williams AD; Reyes SA; Arlow RL; Tchou J; De La Cruz LM
Ann Surg Oncol; 2018 Oct; 25(10):2875-2883. PubMed ID: 29959613
[TBL] [Abstract][Full Text] [Related]
16. Association Between Neutrophil-Lymphocyte Ratio and Oncotype Dx Recurrence Score in Early-Stage Hormonal Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer.
Alshamsan B; Alshibany A; Elshenawy MA; Badran A; Elhassan T; Ajarim D; Alsayed A; Suleman K; Al-Tweigeri T
Cancer Manag Res; 2021; 13():9411-9420. PubMed ID: 35002318
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant Chemotherapy for Patients with Breast Cancer Based on Clinical and Evolving Oncotype DX Criteria.
Zekri J; Al-Foheidi M; Alata M; Zabani R; Rasmy A
Breast Care (Basel); 2020 Dec; 15(6):642-647. PubMed ID: 33447239
[TBL] [Abstract][Full Text] [Related]
18. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
[TBL] [Abstract][Full Text] [Related]
19. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
[TBL] [Abstract][Full Text] [Related]
20. Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX.
Sengupta AK; Gunda A; Malpani S; Serkad CPV; Basavaraj C; Bapat A; Bakre MM
Cancer Med; 2020 Nov; 9(21):7810-7818. PubMed ID: 33027559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
